logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
C

Christof Vulsteke

queen mary university london
H指数:28
被引数:8,180

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Low awareness of and adherence to preventive guidelines for hepatitis B reactivation among Belgian specialist physicians: the CHOICe study

比利时专科医生对乙型肝炎再激活预防指南的认知度及依从性低：CHOICe研究

BMC Gastroenterology
IF2.6
2026-09-220
OA
Marie Coessens; Jolien De Graeve; Cedric Van de Bruaene; Vibeke Kruse; Isabelle Colle; Stefan Bourgeois; Jeroen Maus; Lode Van Overbeke; Maridi Aerts; Hans Orlent; Tom Holvoet; Katelijne De Wilde; Veronique Goeteyn; Christof Vulsteke; Christophe Van Steenkiste; Valérie Lambrecht; Annelies Verbiest; Michaël Somers; Margot Van Mechelen; Olivier Aerts; Ciel De Vriendt; Anja Geerts; Dirk Elewaut; Jo Lambert; Veroniek Saegeman; Thomas Vanwolleghem; Wim Verlinden; Jeoffrey Schouten
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: 1-Year Follow-Up After Final Analysis of the ENGOT-en9/LEAP-001 Phase 3 Trial

一线仑伐替尼联合帕博利珠单抗与化疗治疗晚期子宫内膜癌：ENGOT-en9/LEAP-001 III期试验最终分析后的1年随访

International Journal of Gynecological Cancer
IF4.7
2025-11-110
PRE
Christian Marth; Richard G. Moore; Mariusz Bidziński; Vanda Salutari; Özden Altundağ; Maria Jesús Rubio; Tally Levy; Alison Stillie; Christof Vulsteke; Ralf Witteler; Kazuya Ariyoshi; Xiaohua Wu; Sophia Frentzas; André Mattar; Brian M. Slomovitz; Stephanie Lheureux; Xiaojun Chen; Kosei Hasegawa; Manuel Magallanes; Chel Hun Choi
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract

TROPiCS-04研究的通俗语言摘要：沙西妥珠单抗在铂类化疗和免疫疗法之后，用于患有膀胱、尿道或上尿路局部晚期或转移性癌症的人群

FUTURE ONCOLOGY
IF2.6
2025-11-011
PRE
Powles, Thomas; Tagawa, Scott T.; Vulsteke, Christof; Gross-Goupil, Marine; Park, Se Hoon; Necchi, Andrea; De Santis, Maria; Duran, Ignacio; Morales-Barrera, Rafael; Guo, Jun; Sternberg, Cora N.; Bellmunt, Joaquim; Goebell, Peter J.; Kovalenko, Maria; Boateng, Freda; Sierecki, Mitch; Wang, Lu; Sima, Camelia S.; Waldes, Jana; Bangs, Rick; Loriot, Yohann; Grivas, Petros
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

EV-302研究的探索性亚组分析：一项评估恩诺单抗（enfortumab vedotin）联合帕博利珠单抗（pembrolizumab）与化疗对比治疗既往未治疗的局部晚期或转移性尿路上皮癌的III期全球研究

ESMO Open
IF8.3
2025-08-110
OAAI
M.S. van der Heijden; T. Powles; S. Gupta; Y. Loriot; M.D. Galsky; B.P. Valderrama; S.S. Sridhar; E.Y. Yu; G. Iyer; E. Kikuchi; D. Castellano; J. Hoffman-Censits; A. Drakaki; N. Mar; J.P. Maroto Rey; C. Vulsteke; W. Arafat; I. Duran; N.A. Dawson; U. Swami; S. Gorla; B.H. Moreno; X. Yu; Y.-T. Lu; J. Bedke
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial☆

恩诺单抗维多汀联合帕博利珠单抗治疗未经治疗的局部晚期或转移性尿路上皮癌：III期EV-302/KEYNOTE-A39试验的中位2.5年随访结果☆

Annals of Oncology
IF65.4
2025-06-010
PREAI
T.B. Powles; M.S. Van der Heijden; Y. Loriot; J. Bedke; B.P. Valderrama; G. Iyer; E. Kikuchi; J. Hoffman-Censits; C. Vulsteke; A. Drakaki; S. Rausch; W. Arafat; S.H. Park; U. Swami; J.-R. Li; I. Duran; S. Gorla; B. Homet Moreno; X. Yu; Y.-T. Lu; S. Gupta
Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients
SCIENTIFIC REPORTS
IF3.9
2025-03-060
OAAI
Debie, Yana; Garcia-Fogeda, Irene; Willem, Lander; Roelant, Ella; Verbruggen, Lise; Vanhoutte, Greetje; Croes, Lieselot; Vulsteke, Christof; Demey, Wim; Lybaert, Willem; Hanssens, Marianne; Bols, Alain; Van Ongeval, Johan; De Becker, Ann; Jansens, Hilde; Goossens, Maria E.; Janssens, Annelies; Prenen, Hans; Anguille, Sebastien; Peeters, Marc; van Dam, Peter A.; Hens, Niel; Abrams, Steven; Vandamme, Timon
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial

Sacituzumab govitecan在晚期尿路上皮癌中的应用：TROPiCS-04，一项III期随机试验

ANNALS OF ONCOLOGY
IF65.4
2025-02-014
PRE
Powles, T.; Tagawa, S.; Vulsteke, C.; Gross-Goupil, M.; Park, S. H.; Necchi, A.; De Santis, M.; Duran, I.; Morales-Barrera, R.; Guo, J.; Sternberg, C. N.; Bellmunt, J.; Goebell, P. J.; Kovalenko, M.; Boateng, F.; Sierecki, M.; Wang, L.; Sima, C. S.; Waldes, J.; Loriot, Y.; Grivas, P.
TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis

TROPiCS-04，一项关于sacituzumab govitecan（SG）与化疗（CT）对比治疗经治晚期尿路上皮癌（aUC）的随机III期研究：总生存期（OS）和安全性的分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Grivas, P.; Powles, T. B.; Vulsteke, C.; Goupil, M. Gross; Park, S. H.; Necchi, A.; De Santis, M.; Duran, I.; Morales Barrera, R.; Guo, J.; Sternberg, C. N.; Bellmunt, J.; Goebell, P. J.; Boateng, F.; Sierecki, M.; Wang, L.; Sima, C.; Waldes, J.; Tagawa, S. T.; Loriot, Y.
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ ENGOT-OV26/GOG-3012 trial

新诊断晚期卵巢癌患者的尼拉帕尼一线维持治疗: PRIMA/ ENGOT-OV26/GOG-3012试验的最终总生存期结果

ANNALS OF ONCOLOGY
IF65.4
2024-11-012
OAAI
Monk, B. J.; Barretina-Ginesta, M. P.; Pothuri, B.; Vergote, I.; Graybill, W.; Mirza, M. R.; Mccormicky, C. C.; Lorusso, D.; Moore, R. G.; Freyer, G.; O'Cearbhaill, R. E.; Heitz, F.; O'Malley, D. M.; Redondo, A.; Shahin, M. S.; Vulsteke, C.; Bradley, W. H.; Haslund, C. A.; Chase, D. M.; Pisano, C.; Holman, L. L.; Perez, M. J. Rubio; Disilvestro, P.; Gaba, L.; Herzog, T. J.; Bruchim, I.; Compton, N.; Shtessel, L.; Malinowska, I. A.; Gonzalez-Martin, A.
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
CLINICAL CANCER RESEARCH
IF10.2
2024-10-300
OAAI
Flechon, Aude; Morales-Barrera, Rafael; Powles, Thomas; Alva, Ajjai; Ozguroglu, Mustafa; Csoszi, Tibor; Loriot, Yohann; Rodriguez-Vida, Alejo; Geczi, Lajos; Cheng, Susanna Y.; Fradet, Yves; Oudard, Stephane; Vulsteke, Christof; Gunduz, Seyda; Mamtani, Ronac; Yu, Evan Y.; Montesa Pino, Alvaro; Anido, Urbano; Sendur, Mehmet A. N.; Gravis, Gwenaelle; Revesz, Janos; Kostorov, Vladimir; Huillard, Olivier; Ma, Junshui; Rajasagi, Mohini; Vajdi, Amir; Lunceford, Jared; Cristescu, Razvan; Imai, Kentaro; Homet Moreno, Blanca; Matsubara, Nobuaki
Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPRcompliant analysis of hospital records

真实世界使用和免疫检查点抑制剂（ICI）的不良事件（AE）：一项大规模、自动化的GDPR合规性医院记录分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Verbiest, A. T. L.; Debruyne, P. R.; Bassez, I.; Delombaerde, D. L.; Tack, L.; Oeste, C. L.; Deckx, L.; Croes, L.; Hens, D. F. E.; Geldhof, V.; Prenen, H.; Vulsteke, C.
EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) plus pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

EV-302：探索性分析nectin-4表达及对一线恩夫妥单抗 vedotin（EV）联合帕博利珠单抗（P）的应答，在既往未治疗的局部晚期或转移性尿路上皮癌（la/mUC）中

ANNALS OF ONCOLOGY
IF65.4
2024-09-015
PRE
Powles, T. B.; Van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Rey, J. P. Maroto; Vulsteke, C.; Iyer, G.; Swami, U.; Shin, S. J.; Rodriguez-Vida, A.; Wozniak, M.; Moreno, B. Homet; Lu, J.; Yu, C.; Hogdal, L.; Loriot, Y.
Tolerability of the niraparib individualized starting dose in the PRIMA/ ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

尼拉帕利一线维持治疗的PRIMA/ ENGOT-OV26/GOG-3012试验中尼拉帕利个体化起始剂量的耐受性

EUROPEAN JOURNAL OF CANCER
IF7.1
2024-09-011
PRE
Vulsteke, Christof; Chambers, Setsuko K.; Perez, Maria Jesus Rubio; Chan, John K.; Raaschou-Jensen, Nicoline; Zhuo, Ying; Lorusso, Domenica; Herzog, Thomas J.; Rouge, Thibault de la Motte; Pepin, Jessica A. Thomes; Braicu, Elena Ioana; Chen, Lee-may; Levy, Tally; Barter, James F.; Barretina-Ginesta, M. Pilar; Joosens, Eric; York, Whitney; Malinowska, Izabela A.; Gonzalez-Martin, Antonio; Monk, Bradley J.
TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)

TAMARACK：靶向B7-H3的抗体药物偶联物（ADC）vobramitamab duocarmazine（vobra duo）在转移性去势抵抗性前列腺癌（mCRPC）中的随机化II期试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
de Bono, J. S.; Helissey, C.; Fizazi, K.; Maroto Rey, J. P.; Roubaud, G.; Antonarakis, E. S.; Sandhu, S. K.; Shore, N. D.; Ratta, R.; Perez Valderrama, B.; Vulsteke, C.; Schafer, L.; Marr, G.; Zhao, E.; Ward, A. F.; Piulats Rodriguez, J. M.
Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63
SCIENTIFIC REPORTS
IF3.9
2024-08-081
OAAI
Martinez-Campelo, L.; Blanco-Verea, A.; Lopez-Fernandez, T.; Martinez-Monzonis, A.; Buno, A.; Mazon, P.; Zamora, P.; Norton, N.; Reddy, J. S.; Velasco-Ruiz, A.; Gonzalez-Neira, A.; Vulsteke, C.; Alonso-Gordoa, T.; Cruz, R.; Diz-de Almeida, S.; Carracedo, A.; Gonzalez-Juanatey, JR.; Lopez-Sendon, J.; Brion, M.
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy

EV-301既往接受过治疗的晚期尿路上皮癌患者的健康相关生活质量: Enfortumab Vedotin与化疗的3期试验

EUROPEAN UROLOGY
IF25.2
2024-06-014
OAAI
Rosenberg, Jonathan E.; Mamtani, Ronac; Sonpavde, Guru P.; Loriot, Yohann; Duran, Ignacio; Lee, Jae-Lyun; Matsubara, Nobuaki; Vulsteke, Christof; Castellano, Daniel; Sridhar, Srikala S.; Pappot, Helle; Gurney, Howard; Bedke, Jens; van der Heijden, Michiel S.; Galli, Luca; Keam, Bhumsuk; Masumori, Naoya; Meran, Johannes; O'Donnell, Peter H.; Park, Se Hoon; Grande, Enrique; Sengelov, Lisa; Uemura, Hiroji; Skaltsa, Konstantina; Campbell, Mary; Matsangou, Maria; Wu, Chunzhang; Hepp, Zsolt; Mckay, Caroline; Powles, Thomas; Petrylak, Daniel P.

研究方向

暂未获取到该数据
L
Lieselot Croes
H 指数:11论文数:59被引数:546
M
Marc Peeters
H 指数:99论文数:1,379被引数:4.6万
T
Thomas Powles
H 指数:77论文数:691被引数:3.7万
H
Hans Prenen
H 指数:54论文数:435被引数:1.5万
Y
Yohann Loriot
H 指数:76论文数:1,129被引数:5.4万
P
Peter A. van Dam
H 指数:59论文数:390被引数:1.0万
M
Michiel S. van der Heijden
H 指数:53论文数:341被引数:2.6万
D
D.L. Delombaerde
H 指数:5论文数:19被引数:98
B
Begoña P. Valderrama
H 指数:25论文数:176被引数:6,900
I
Ignacio Durán
H 指数:54论文数:346被引数:1.7万